26-JUL-2024 6:10

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY ADMIN CCADMIN ACCR.
GOAL		 R
E
G		 O
P
E
N		 ARM TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol PEOLC   817 1 T 0 Screening 329 12 0 0 0 0
              329 12 0 0 0 0
 
        2 T 1 Carvedilol 74 5 0 0 0 0
            2 No prophylaxis 81 7 0 0 0 0
            3 Observation 155 0 0 0 0 0
              310 12 0 0 0 0
 
S1703-Met Breast, STM-monitoring v Usual Care CCD SXQOL 739 1 Y 0 Screening 512 72 36 21 5 1
              512 72 36 21 5 1
 
        2 Y 1 Control (Usual Care) 172 25 15 7 2 0
            2 Intervention (STMDDM) 174 29 16 6 2 0
              346 54 31 13 4 0
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum GU SXQOL 1273 1 Y 0 Induction SST 829 129 70 36 14 6
              829 129 70 36 14 6
 
        2 Y 1 Standard Systemic Therapy Only 288 37 18 10 2 0
            2 SST + Surgery/RT 294 43 23 15 5 1
              582 80 41 25 7 1
 
S1803-MM, Maintenance, Len vs Len/Dara MMYEL SXQOL 1420 1 Y 0 Screening 1289 148 126 68 14 3
              1289 148 126 68 14 3
 
        2 Y 1 Lenalidomide 594 69 57 36 7 2
            2 Lenalidomide + Daratumumab 586 72 64 33 7 1
              1180 141 121 69 14 3
 
        3 Y 3 Continue Lenalidomide 29 13 4 2 2 0
            4 Stop Lenalidomide 29 14 4 2 0 0
            5 Continue Lenalidomide + Dara 68 27 12 5 1 0
            6 Stop Lenalidomide + Dara 68 26 11 6 3 0
              194 80 31 15 6 0
 
S1827-SCLC, MRI Surveillance +/- PCI LUNG SXQOL 668 1 Y 1 PCI + MRI brain surveillance 114 35 17 8 2 0
            2 MRI brain surveillance 116 35 23 9 3 0
              230 70 40 17 5 0
 
S1912CD-CREDIT, Fin Counseling to reduce Fin Hardship CCD   326 1 Y 1 Financial Navigation 131 85 42 17 6 0
            2 Control 137 90 45 24 13 1
              268 175 87 41 19 1
 
S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo LUNG SXQOL 480 1 Y 1 Atezolizumab and SBRT 201 85 47 22 11 1
            2 SBRT 199 84 44 27 8 2
              400 169 91 49 19 3
 
S1918-DLBCL, Adv, Age 75+, CC-486 +/- R-miniCHOP LYMPH SXQOL 422 1 Y 1 CC-486 + R-miniCHOP 55 24 11 6 2 0
            2 R-miniCHOP 56 28 14 9 5 0
              111 52 25 15 7 0
 
S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O LEUK SXQOL 247 1 Y 1 Delayed V-O 38 12 6 3 2 0
            2 Early V-O 72 24 13 7 3 1
              110 36 19 10 5 1
 
S2010-ASPEN: Brst, Stg I-III, ASM vs Pt Ed SXQOL   540 1 Y 1 Active Symptom Monitoring + Patient Education 184 158 93 46 13 4
            2 Patient Education 182 155 90 42 11 4
              366 313 183 88 24 8
 
S2013-I-CHECKIT: ICI toxicity risk prediction study SXQOL   2062 1 T 1 Observation Arm 2084 836 322 39 0 0
              2084 836 322 39 0 0
 
S2108CD-Genomic Tumor Board vs Usual Practice CCD   1182 1 Y 1 Usual Practice 512 275 146 85 31 5
            2 EGTB Intervention 595 356 144 67 18 2
              1107 631 290 152 49 7
 
S2205-ICE COMPRESS: Reduction of CIPN from Taxanes SXQOL   777 1 Y 1 Cryocompression 61 59 37 18 7 2
            2 Continuous Compression 61 59 35 18 7 1
            3 Low Cyclic Compression 64 60 38 22 8 2
              186 178 110 58 22 5
 
S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva BREAST SXQOL 960 1 Y 1 Tissue for MammaPrint testing 125 125 118 74 26 5
              125 125 118 74 26 5
 
        2 Y 2 SOC Chemotherapy 16 16 16 12 3 0
            3 SOC Chemotherapy + Durvalumab 16 16 16 12 3 1
              32 32 32 24 6 1
 
S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa LYMPH SXQOL 227 1 Y 1 Tazemetostat (Arm 1) Dose Level 1 7 7 6 4 0 0
            4 Zanubrutinib (Arm 3) Dose Level 1 10 10 6 0 0 0
            5 Zanubrutinib (Arm 3) Dose Level 2 4 4 4 4 4 1
              21 21 16 8 4 1
 
S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D MMYEL SXQOL 510 1 Y 1 VRD-R 10 10 6 3 1 0
            2 DRD-R 11 11 7 4 2 0
            3 DRD-DR 9 9 6 3 0 0
              30 30 19 10 3 0
 
S2212-Breast, TNBC, Neoadj Chemo + Pembro BREAST SXQOL 2400 1 Y 1 Carbo + Paclitaxel + Pembro -> AC + Pembro 111 111 91 52 17 4
            2 Carbo + Docetaxel + Pembro 110 110 89 55 17 3
              221 221 180 107 34 7
 
S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT MMYEL SXQOL 338 1 Y 0 Induction 1 1 1 1 1 0
              1 1 1 1 1 0
 
        2 Y   0 0 0 0 0 0
              0 0 0 0 0 0
 
        3 Y   0 0 0 0 0 0
              0 0 0 0 0 0
 
S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo GI SXQOL 224 1 Y 2 Paclitaxel + Ramucirumab 1 1 1 1 0 0
              1 1 1 1 0 0
 
A011801-BRST, HER2+, T-DM1+Placebo v T-DM1+Tucatinib BREAST SXQOL   1 E   44 15 4 2 0 0
              44 15 4 2 0 0
 
A012103-Breast,StgT1cN1-2/T2-4N0-2,obsvsPembrolizumab BREAST SXQOL   1 E   8 8 4 3 0 0
              8 8 4 3 0 0
 
A021806-Pancreas, Perioperative vs Adjuvant Chemo GI SXQOL   0 E   36 9 2 1 0 0
              36 9 2 1 0 0
 
        1 E   30 8 2 1 0 0
              30 8 2 1 0 0
 
A022001-PANC, METS, Lu 177 Dotatate PRRT vs CAPTEM GI SXQOL   1 E   2 1 0 0 0 0
              2 1 0 0 0 0
 
A022004-Colon, Stg II-III, Encor+Cetux vs SOC GI SXQOL   0 E   10 10 10 7 4 3
              10 10 10 7 4 3
 
        1 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
A032103-Urothelial, All Stg, MRD-Based Adj Tx GU SXQOL   0 E   2 2 2 1 0 0
              2 2 2 1 0 0
 
        1 E   2 2 2 2 1 0
              2 2 2 2 1 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
A052101-Lymph, Stg I-IV, Cont v Intermittent Zanub LYMPH SXQOL   1 E   7 7 6 2 2 0
              7 7 6 2 2 0
 
        2 E   1 1 0 0 0 0
              1 1 0 0 0 0
 
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO LUNG SXQOL   1 E   80 18 10 5 4 1
              80 18 10 5 4 1
 
A211901-Cancer survivors who smoke, txt cessation SURV     1 E   11 11 8 6 2 0
              11 11 8 6 2 0
 
ACCL16N1-Guideline Consistent Treatment AYA ALL CCD     1 T   54 0 0 0 0 0
              54 0 0 0 0 0
 
AHOD2131-cHL,StgI-II,StdTherapyvImmuno-oncologyTherapy LYMPH SXQOL   1 E   20 20 8 3 1 1
              20 20 8 3 1 1
 
        2 E   14 14 5 1 0 0
              14 14 5 1 0 0
 
CCTGHN11-HN, All Stg, Guided Elec Contra Neck Tx OTHER SXQOL   1 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
        2 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) MMYEL SXQOL   0 E   46 15 2 0 0 0
              46 15 2 0 0 0
 
        1 E   35 12 3 0 0 0
              35 12 3 0 0 0
 
        2 E   22 13 7 5 1 0
              22 13 7 5 1 0
 
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT BREAST SXQOL   1 E   33 14 11 4 3 1
              33 14 11 4 3 1
 
        2 E   32 13 10 4 3 1
              32 13 10 4 3 1
 
NRGCC010-Endo, Stg I, LN Map for LE Limb Dysfunction SXQOL OTHER   1 E   10 6 4 3 0 0
              10 6 4 3 0 0
 
NRGCC011-Breast, Survivors, Cog Training SXQOL     0 E   4 4 4 3 2 0
              4 4 4 3 2 0
 
        1 E   2 2 2 1 1 0
              2 2 2 1 1 0
 
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide GU SXQOL   1 E   14 6 4 1 1 0
              14 6 4 1 1 0
 
NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx GU SXQOL   1 E   9 8 1 0 0 0
              9 8 1 0 0 0
 
NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo LUNG SXQOL   1 E   1 1 1 0 0 0
              1 1 1 0 0 0
 
A021804-Adren, Advanced Stg, Temo w/wo Ola GU     1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
A031801-GU, mRCC, Cabozantinib +/- Radium-223 GU SXQOL   1 E   15 5 2 1 0 0
              15 5 2 1 0 0
 
A082002-Lung, Adv, Systemic Tx +/- SBRT LUNG SXQOL   1 E   4 1 0 0 0 0
              4 1 0 0 0 0
 
A191901-Brst, Text/Motivational Intervention ET Adher CCD     1 E   40 1 1 1 1 0
              40 1 1 1 1 0
 
A211801-Breast, Preventive, Denosumab PREV     0 E   1 1 1 1 1 0
              1 1 1 1 1 0
 
        1 E   1 1 1 1 1 0
              1 1 1 1 1 0
 
A212102-Blind Ref Set for Multicancer Early Detection PREV     1 E   123 77 54 29 13 2
              123 77 54 29 13 2
 
A222004-Mult, Olanza vs Megestrol for Anorexia SXQOL     1 E   6 4 3 3 3 0
              6 4 3 3 3 0
 
A231602C-Blood Cancer, Assess Financial Difficulty CCD     1 T   4 0 0 0 0 0
              4 0 0 0 0 0
 
A231901C-Breast, Shared Decision Engagement System CCD SXQOL   1 E   2 1 0 0 0 0
              2 1 0 0 0 0
 
ACCL1931-Leuk, All Stg, Levocarnitine Prophylaxis SXQOL     1 E   2 2 2 0 0 0
              2 2 2 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
AGCT1531-Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult ERLYTX SXQOL   1 E   2 0 0 0 0 0
              2 0 0 0 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo OTHER SXQOL   1 T   4 0 0 0 0 0
              4 0 0 0 0 0
 
CCTGCO32-Rectal, Early Stg, Neoadj/Exc/Obs vs ChemRad GI SXQOL   1 E   1 1 1 1 1 0
              1 1 1 1 1 0
 
CCTGNE1-Midgut NET, Unresect, 177 Lut vs Ever GI SXQOL   1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
CE7-Brain, 5+ Metastases, Radiosurg/Radiotherapy OTHER SXQOL   1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
        2 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
EA2182-Anal, Erly, DECREASE GI SXQOL   0 E   13 6 1 1 0 0
              13 6 1 1 0 0
 
        1 E   14 6 1 1 0 0
              14 6 1 1 0 0
 
EA2185-Panc, Impact of Panc Cyst Surveillance PREV SXQOL   1 E   19 5 1 0 0 0
              19 5 1 0 0 0
 
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL   1 E   13 2 1 1 0 0
              13 2 1 1 0 0
 
        2 E   0 0 0 0 0 0
              0 0 0 0 0 0
 
EA8184-Pros, Dbl Blind GTC vs Placebo PREV SXQOL   0 E   16 11 5 2 2 0
              16 11 5 2 2 0
 
        1 E   6 4 2 2 0 0
              6 4 2 2 0 0
 
EA8191-Pros, Local vs Systemic Thrpy GU SXQOL   0 E   43 22 16 13 3 0
              43 22 16 13 3 0
 
        1 E   43 22 16 13 3 0
              43 22 16 13 3 0
 
EA8212-Blad, NMIBC, BRIDGE GU SXQOL   1 E   130 99 60 26 6 0
              130 99 60 26 6 0
 
EAA173-MYEL, SMM, Rd +/- Daratumumab MMYEL SXQOL   0 E   70 18 12 7 2 0
              70 18 12 7 2 0
 
        1 E   32 9 6 5 0 0
              32 9 6 5 0 0
 
EAQ202-Improving AYA PROs in EA Trials SXQOL     1 E   43 0 0 0 0 0
              43 0 0 0 0 0
 
NRGBN003-Mening, Grd II, Observation vs Irradiation OTHER SXQOL   1 E   5 0 0 0 0 0
              5 0 0 0 0 0
 
        2 E   3 0 0 0 0 0
              3 0 0 0 0 0
 
NRGBN011-Brain, Lomustine + Temo vs Temo OTHER SXQOL   1 E   20 14 5 5 1 1
              20 14 5 5 1 1
 
        2 E   5 3 1 1 1 1
              5 3 1 1 1 1
 
NRGBN012-Brain, Pre- vs Post-Op Stereotactic Radiosurg OTHER SXQOL   1 E   4 3 3 3 2 0
              4 3 3 3 2 0
 
NRGBR007-Breast, Stg I, De-Escalation of Breast RT BREAST SXQOL   1 E   9 4 1 1 0 0
              9 4 1 1 0 0
 
        2 E   9 4 1 1 0 0
              9 4 1 1 0 0
 
NRGBR009-Breast, EarlyStg, Adjuvant Chemo BREAST SXQOL   1 E   5 5 5 2 2 0
              5 5 5 2 2 0
 
        2 E   4 4 4 1 1 0
              4 4 4 1 1 0
 
NRGCC005-Colon,Non-AdvancedAdenomas,Colonoscopy5v10yrs PREV     1 E   12 12 11 8 3 1
              12 12 11 8 3 1
 
NRGCC008-Ovar, BRCA1, non-inferiority of BLS vs BSO PREV SXQOL   1 E   10 4 2 1 1 0
              10 4 2 1 1 0
 
NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy GI SXQOL   1 Y   15 0 0 0 0 0
              15 0 0 0 0 0
 
NRGGI006-Esophagus, Stg I-IVA, PBT vs IMRT GI SXQOL   1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
        2 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
NRGGU009-Pros, PREDICT-RT GU SXQOL   1 E   69 49 28 19 7 0
              69 49 28 19 7 0
 
        2 E   65 48 26 18 9 2
              65 48 26 18 9 2
 
NRGGU010-Pros, Parallel De-Intens & Intens Trials GU SXQOL   1 E   41 23 11 7 1 1
              41 23 11 7 1 1
 
        2 E   37 20 9 6 1 1
              37 20 9 6 1 1
 
NRGGU013-Prostate, High-Risk, Five Fraction Radiation GU SXQOL   1 E   2 2 2 2 0 0
              2 2 2 2 0 0
 
NRGGY026-Endomet, Stage I-IV, Pac/Car w/ HER HYL/PHE OTHER SXQOL   1 E   1 1 1 1 0 0
              1 1 1 1 0 0
 
NRGHN005-HN, early stg P16-pos, randomize de-intensifi OTHER SXQOL   1 E   8 1 0 0 0 0
              8 1 0 0 0 0
 
NRGHN006-HN, Erly Stg, Biopsy vs Dissection OTHER SXQOL   1 E   2 1 1 1 1 0
              2 1 1 1 1 0
 
        2 E   2 0 0 0 0 0
              2 0 0 0 0 0
 
NRGHN009-HN, RT + HD Cisp vs RT + LD Cisp for SCCHN OTHER SXQOL   1 E   16 9 5 2 1 0
              16 9 5 2 1 0
 
R1216-HN, Adv,Cis vs Dtx vs Dtx+Cetux OTHER SXQOL   1 E   6 0 0 0 0 0
              6 0 0 0 0 0
 
        2 E   5 0 0 0 0 0
              5 0 0 0 0 0
 

26-JUL-2024 6:10

Cancer Coltrol Open Studies with No Registrations

Study Admin CCAdmin Registration/Phase Open Date
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT MMYEL SXQOL 2 Randomization 01-Dec-23
  MMYEL SXQOL 3 Maintenance 01-Dec-23
A022004 Colon, Stg II-III, Encor+Cetux vs SOC GI SXQOL 1 Registration 30-May-23
A032103 Urothelial, All Stg, MRD-Based Adj Tx GU SXQOL 2 Re-Registration 09-Jan-24
ACCL1931 Leuk, All Stg, Levocarnitine Prophylaxis SXQOL   2 Callback 14-Aug-23
AGCT1531 Mult, Stg I-IV, Carbo vs Cisp, Ped &Adult ERLYTX SXQOL 2 Late Randomization Callback 08-May-17
EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT GU SXQOL 2 Randomization2 08-Sep-17